Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
MWN-AI** Summary
On November 24, 2025, Shanghai Junshi Biosciences Co., Ltd. announced that its Phase 3 clinical trial, JS001sc-002-III-NSCLC, has successfully met its primary endpoints. This multi-center, open-label, randomized study evaluated the efficacy of toripalimab injection administered subcutaneously (JS001sc) compared to the standard intravenous toripalimab (JS001) in conjunction with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small-cell lung cancer (NSQ-NSCLC).
The study's success is particularly significant as NSCLC represents approximately 85% of lung cancer cases, with non-squamous variants accounting for 65% of these cases. Given the rising incidence of lung cancer in China, with over 1 million new cases reported in 2022, there is a pressing need for more accessible treatment options. Currently, intravenous immunotherapy protocols can be cumbersome for patients due to lengthy infusion times.
Dr. Jianjun Zou, Junshi's CEO, underscored the importance of this study in making immunotherapy more convenient for patients, aiming to reduce healthcare burdens and improve treatment experiences. The results of the trial indicated that the exposure to JS001sc was non-inferior to that of intravenous toripalimab, showing comparable efficacy and safety profiles. Junshi plans to submit a new drug application to regulatory authorities soon.
JS001sc is notable for being the first domestic anti-PD-1 monoclonal antibody offered in a subcutaneous format, marking a significant advancement in the delivery of immunotherapies. With a diversified R&D pipeline and a commitment to innovative therapeutic solutions, Junshi Biosciences continues to position itself as a leader in the biopharmaceutical industry, dedicated to enhancing patient care.
MWN-AI** Analysis
Junshi Biosciences’ announcement regarding the success of the Phase 3 clinical study for the subcutaneous formulation of toripalimab (JS001sc) presents a compelling investment opportunity ahead of its anticipated new drug application (NDA) submission. This innovative approach to combat non-squamous non-small-cell lung cancer (NSQ-NSCLC) addresses an urgent clinical need for more convenient treatment options, given the burdensome intravenous administration of existing immunotherapies.
The fact that JS001sc demonstrated non-inferior drug exposure and similar efficacy and safety to its intravenous counterpart can significantly influence market sentiment. As lung cancer remains a leading cause of cancer mortality in China, with over 1 million new cases annually, Junshi’s enhanced administration method may not only increase adoption rates among healthcare providers but also improve patient compliance, thereby expanding its potential market share.
Furthermore, Junshi's strategic positioning as a pioneer in the subcutaneous anti-PD-1 category demonstrates its ability to innovate within a competitive landscape dominated by established products. This innovation could attract investors looking for growth in the biopharmaceutical sector, especially within oncology, an area that garners significant funding and attention due to high unmet medical needs.
Additionally, the data presentation at an upcoming international academic conference could amplify visibility and bolster confidence among investors and stakeholders alike. However, potential investors should remain mindful of the regulatory landscape and market competition, particularly as Junshi seeks to navigate NDA approvals.
In conclusion, with its promising trial results, Junshi Biosciences is well-poised for potential growth. Investors interested in biotechnology should closely monitor the company’s progress and consider it a worthy candidate for inclusion in a diversified portfolio focused on innovative health solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab injection (subcutaneous injection) (code: JS001sc) or toripalimab injection (code: JS001) in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small-cell lung cancer ("NSQ-NSCLC") (NCT06505837). Junshi Biosciences plans to submit a new drug application ("NDA") to the regulatory authorities in the near future.
According to data released by GLOBOCAN 2022, in 2022, China saw 1.06 million new lung cancer cases (22.0% of all new cancer cases in China) and 0.73 million lung cancer deaths (28.5% of all cancer-related deaths in China). NSCLC was the predominant subtype, accounting for approximately 85% of all lung cancer cases. Among NSCLC patients, non-squamous NSCLC constituted approximately 65% of cases.
Immunotherapy (I-O), represented by anti-PD-1 monoclonal antibodies, has become a cornerstone treatment for various malignant tumors including lung cancer, breast cancer, liver cancer, esophageal cancer, and nasopharyngeal carcinoma. Now, immunotherapy covers nearly all stages of treatment for cancer patients, encompassing adjuvant/neoadjuvant treatment for early-stage tumors, consolidation treatment after radical chemoradiation for locally advanced tumors, and first-line to last-line treatments for advanced tumors. Currently, most immunotherapy drugs in China are administered intravenously, and this not only requires lengthy infusion times, but also imposes significant inconveniences on patients. There is an urgent clinical need for more convenient administration methods for immunotherapy.
The JS001sc-002-III-NSCLC Study is a multi-center, open-label, randomized Phase 3 clinical study led by the principal investigator Professor Lin WU from Hunan Cancer Hospital. JS001sc-002-III-NSCLC is the first Phase 3 clinical study of a domestic anti-PD-1 monoclonal antibody subcutaneous formulation.
The study aims to compare the exposure, efficacy and safety of JS001sc plus chemotherapy or JS001 plus chemotherapy for the first-line treatment of recurrent or metastatic NSQ-NSCLC. The results have showed that the drug exposure of JS001sc was non-inferior to that of toripalimab injection with comparable efficacy and safety profiles. The study data will be presented at an upcoming international academic conference. Junshi Biosciences plans to communicate with the regulatory authorities and submit JS001sc’s NDA for all approved indications of JS001.
Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, “Since its launch as China's first domestically developed PD-1 antibody drug, toripalimab has secured approvals for 12 indications, benefiting a significant number of patients. In clinical practice, we observed that patients undergoing immunotherapy, either as monotherapy or combination maintenance therapy, face challenges such as frequent intravenous catheterization and time-consuming infusions. The recent success of the Phase 3 study for JS001sc, achieved through the efforts of both patients and the research team, marks not only a pivotal breakthrough in transitioning I-O therapy from 'efficacy' to 'convenience', but also exemplifies Junshi Biosciences' patient-centric ambition. By innovating drug delivery methods, we enhance treatment accessibility: simplifying procedures for patients, reducing their healthcare burden, and alleviating pressure on medical resources. We are committed to advancing the registration of JS001sc and providing more patients with a better treatment experience alongside clinical benefits.”
About JS001sc
JS001sc, developed by Junshi Biosciences, is a subcutaneous injection formulation based on the marketed product, toripalimab injection. JS001sc is the first domestic anti-PD-1 monoclonal antibody subcutaneous formulation to enter Phase 3 clinical study, and will potentially offer more convenient administration to patients. As of today, a multi-center, open-label, randomized Phase 3 clinical study comparing JS001sc plus chemotherapy or toripalimab injection plus chemotherapy for the first-line treatment of recurrent or metastatic NSQ-NSCLC (the JS001sc-002-III-NSCLC Study) has met its primary endpoints.
About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 40 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19.
With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com.
Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800
PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800
FAQ**
How will the success of the JS001sc-002-III-NSCLC study impact Shanghai Junshi SHJBF's market position in the immunotherapy landscape for lung cancer treatments?
What are the anticipated regulatory challenges Shanghai Junshi SHJBF may face when submitting the NDA for JS001sc, and how might these affect its timeline for commercialization?
How does Shanghai Junshi SHJBF plan to leverage the results from the JS001sc study to enhance patient access and convenience in the administration of its therapies compared to existing treatments?
Given the competitive landscape of immunotherapy drugs, what strategies is Shanghai Junshi SHJBF employing to differentiate JS001sc from other subcutaneous formulations in the market?
**MWN-AI FAQ is based on asking OpenAI questions about Shanghai Junshi (OTC: SHJBF).
NASDAQ: SHJBF
SHJBF Trading
-82.07% G/L:
$3 Last:
1,000 Volume:
$3 Open:
